Serbia
Tuberculosis profile
Population  2013 9.5 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.14–0.16) 1.6 (1.4–1.7)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0–0.02)
Prevalence  (includes HIV+TB) 2.6 (1.3–4.3) 28 (14–46)
Incidence  (includes HIV+TB) 1.7 (1.6–1.9) 18 (17–20)
Incidence (HIV+TB only) 0.012 (<0.01–0.02) 0.12 (0.05–0.22)
Case detection, all forms (%) 120 (110–130)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.85 (0.31–1.8) 4.7 (1.3–11)
MDR-TB cases among notified pulmonary
TB cases
14 (5–30) 6 (2–15)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 004   93
Pulmonary, clinically diagnosed 599   16
Extrapulmonary 385   9
       
Total new and relapse 2 106    
Previously treated, excluding relapses 21    
Total cases notified 2 127    
Among 1 184 new and relapse cases:
14 (1%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 705 (70%) 86 (62%) 792
Laboratory-confirmed RR-/MDR-TB cases     12
Patients started on MDR-TB treatment     10
TB/HIV 2013 Number (%)
TB patients with known HIV status 106 (5)
HIV-positive TB patients 19 (18)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 19 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012 73
HIV-positive TB cases, all types, registered in 2012 100
RR-/MDR-TB cases started on second-line treatment in 2011 64
XDR-TB cases started on second-line treatment in 2011 100
Laboratories 2013  
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 15.2
Drug susceptibility testing (per 5 million population) 2.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 14
% Funded domestically 82%
% Funded internationally 10%
% Unfunded 7%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-03 Data: www.who.int/tb/data